A Study of LY3209590 in Participants With Type 1 Diabetes
A Study of LY3209590 in Participants With Type 1 Diabetes
The reason for this study is to see if the study drug LY3209590 is safe and effective in
 participants with type 1 diabetes.
Inclusion Criteria:

 -  Participants must have a diagnosis of type 1 diabetes mellitus for at least 1 year

 -  Participants must have been using multiple daily injections without interruption for
 at least 3 months

 -  Participants must have HbA1c values of 5.6% to 9.5%, inclusive

 -  Participants must have a body mass index (BMI) of ≤35 kilograms per meter squared
 (kg/m²)

 Exclusion Criteria:

 -  Have had more than 1 emergency room visit or hospitalization due to poor glucose
 control within 6 months prior to study screening

 -  Have any episodes of severe hypoglycemia and/or hypoglycemia unawareness within the 6
 months prior to screening

 -  Have any of the following cardiovascular (CV) conditions: acute myocardial infarction,
 New York Heart Association Class III or IV heart failure, or cerebrovascular accident
 (stroke)

 -  Have acute or chronic hepatitis, or obvious clinical signs or symptoms of any other
 liver disease

 -  Have an estimated glomerular filtration rate (eGFR) <30 milliliters/minute/1.73 m²

 -  Have active or untreated cancer

 -  Are receiving chronic (>14 days) systemic glucocorticoid therapy